80
78- Lok AS, Liang RH, Chiu EK, Wong KL, Chan TK, Todd D. Reactivation of
hepatitis B virus replication in patients receiving cytotoxic therapy. Report
of a prospective study. Gastroenterology 1991; 100:182-188.
79- Kumagai K, Takagi T, Nakamura S, Sawada U, Kura Y, Kodama F, et al.
Hepatitis B virus carriers in the treatment of malignant lymphoma: an
epidemiological study in Japan. Ann Oncol 1997; (Suppl 1):107-109.
80- Markovic S, Drozina G, Vovk M, Fidler-Jenko M. Reactivation of hepatitis
B but not hepatitis C in patients with malignant lymphoma and
immunosuppressive therapy. A prospective study in 305 patients.
Hepatogastroenterology 1999; 46:2925-2930.
81- Liang R, Lau GK, Kwong YL. Chemotherapy and bone marrow
transplantation for cancer patients who are also chronic hepatitis B
carriers: a review of the problem. J Clin Oncol 1999; 17:394-398.
82- Saibara T, Maeda T, Miyazaki M, Onishi S, Yamamoto Y. Assessment of
lymphokine-activated killer activity and γ-interferon production in patients
with small hepatocellular carcinomas. Hepatology 1993; 17:781-787.
83- Protzer-Knolle U, Naumann U, Bartenschlager R, Berg T, Hopf U, Meyer
zum Buschenfelde KH, et al. Hepatitis B virus with antigenically altered
hepatitis B surface antigen is selected by high-dose hepatitis B immune
globulin after liver transplantation. Hepatology 1998; 27: 254-263.
84- Ghany MG, Ayola B, Villamil FG, Gish RG, Rojter S, Vierling JM, et al.
Hepatitis B virus S mutants in liver transplant recipients who were
reinfected despite hepatitis B immune globulin prophylaxis. Hepatology
1998; 27: 213-222.
85- Trautwein C. Mechanisms of hepatitis B virus graft reinfection and graft
damage after liver transplantation. J Hepatol 2004; 41: 362-369.